Technical Analysis for RLMD - Relmada Therapeutics, Inc.

Grade Last Price % Change Price Change
C 5.52 1.85% 0.10
RLMD closed up 1.85 percent on Monday, March 18, 2024, on 53 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 21
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish 1.85%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.85%
Outside Day Range Expansion 1.85%
Lower Bollinger Band Touch Weakness 1.85%
Oversold Stochastic Weakness 1.85%
New Downtrend Bearish 9.74%
Below Lower BB Weakness 9.74%
Gapped Down Weakness 9.74%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 20 hours ago
Up 5% about 20 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 22 hours ago
Rose Above Previous Day's High about 22 hours ago
Up 3% about 22 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists

Is RLMD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.2225
52 Week Low 2.0
Average Volume 232,289
200-Day Moving Average 3.42
50-Day Moving Average 4.88
20-Day Moving Average 5.92
10-Day Moving Average 5.84
Average True Range 0.48
RSI (14) 49.49
ADX 40.86
+DI 23.01
-DI 23.03
Chandelier Exit (Long, 3 ATRs) 5.79
Chandelier Exit (Short, 3 ATRs) 6.24
Upper Bollinger Bands 6.77
Lower Bollinger Band 5.08
Percent B (%b) 0.26
BandWidth 28.40
MACD Line 0.14
MACD Signal Line 0.32
MACD Histogram -0.1778
Fundamentals Value
Market Cap 166.15 Million
Num Shares 30.1 Million
EPS -3.71
Price-to-Earnings (P/E) Ratio -1.49
Price-to-Sales 0.00
Price-to-Book 1.63
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.87
Resistance 3 (R3) 5.90 5.81 5.81
Resistance 2 (R2) 5.81 5.73 5.80 5.79
Resistance 1 (R1) 5.67 5.67 5.74 5.64 5.77
Pivot Point 5.58 5.58 5.62 5.57 5.58
Support 1 (S1) 5.44 5.50 5.51 5.41 5.27
Support 2 (S2) 5.35 5.44 5.34 5.25
Support 3 (S3) 5.21 5.35 5.23
Support 4 (S4) 5.18